COVID-19 Infection in Pregnancy: PCR Cycle Thresholds, Placental Pathology, and Perinatal Outcomes

Viruses

Estibalitz Laresgoiti-Servitje¹  Mónica Aguinaga-Ríos²  María Yolotzin Valdespino-Vázquez³  Rafael Galván-Contreras⁴  Juan Carlos Rodriguez-Aldama⁴  Isabel Villegas-Mota⁴  Claudine Irles⁵  Rosa Gabriela Hernández-Cruz⁶  Mario Solis-Paredes⁷  Addy Cecilia Helguera-Repetto⁸  Moisés León-Juárez⁸  Ricardo Figueroa-Damián⁹  Sandra Acevedo-Gallegos^1,10  María de Lourdes Gómez-Sousa^1,11  Jorge Arturo Cardona-Pérez^1,12  Manuel Cortés-Bonilla^1,13  Guadalupe Estrada-Gutierrez^1,14  Mario Rodríguez-Bosch^1,15  Alejandro Ortiz-Calvillo^1,16  Salvador Espino-y-Sosa^1,16  Irma Coronado-Zarco^1,17  Elsa Romelia Moreno-Verduzco^1,18  María Antonieta Rivera-Rueda^1,19  Carolina Valencia-Contreras^2,20 

[1] Clinical Sciences, School of Medicine and Health Sciences, Tecnológico de Monterrey, Mexico City 64849, Mexico;Coordinación de Genética Clínica, Departamento de Medicina Materno-Fetal, Instituto Nacional de Perinatología, Mexico City 11000, Mexico;Departamento de Anatomía Patológica, Instituto Nacional de Perinatología, Mexico City 11000, Mexico;Departamento de Enfermedades Infecciosas e Epidemiología, Instituto Nacional de Perinatología, Mexico City 11000, Mexico;Departamento de Fisiología y Desarrollo Celular, Instituto Nacional de Perinatología, Mexico City 11000, Mexico;Departamento de Fomento y Herramientas Educativas, Instituto Nacional de Perinatología, Mexico City 11000, Mexico;Departamento de Genética y Genómica Humana, Instituto Nacional de Perinatología, Mexico City 11000, Mexico;Departamento de Immunobioquímica, Instituto Nacional de Perinatología, Mexico City 11000, Mexico;Departamento de Infectología e Inmunología, Instituto Nacional de Perinatología, Mexico City 11000, Mexico;Departamento de Medicina Materno-Fetal, Instituto Nacional de Perinatología, Mexico City 11000, Mexico;Departamento de Posgrado e Investigación, Instituto Nacional de Perinatología, Mexico City 11000, Mexico;Dirección General, Instituto Nacional de Perinatología, Mexico City 11000, Mexico;Dirección Médica, Instituto Nacional de Perinatología, Mexico City 11000, Mexico;Dirección de Investigación, Instituto Nacional de Perinatología, Mexico City 11000, Mexico;Subdirección de Ginecología e Obstetricia, Instituto Nacional de Perinatología, Mexico City 11000, Mexico;Subdirección de Investigación Clínica, Instituto Nacional de Perinatología, Mexico City 11000, Mexico;Subdirección de Neonatología, Instituto Nacional de Perinatología, Mexico City 11000, Mexico;Subdirección de Servicios Auxiliares de Diagnóstico, Instituto Nacional de Perinatología, Mexico City 11000, Mexico;Unidad de Cuidados Intensivos del Recién Nacido, Instituto Nacional de Perinatología, Mexico City 11000, Mexico;Unidad de Cuidados Intermedios del Recién Nacido, Instituto Nacional de Perinatología, Mexico City 11000, Mexico;

关键词: SARS-CoV-2;    pregnancy;    hypertensive disorder;    placenta;   

DOI  :  10.3390/v13091884

来源: DOAJ

【 摘 要 】

(1) This study aimed to evaluate characteristics, perinatal outcomes, and placental pathology of pregnant women with or without SARS-CoV-2 infection in the context of maternal PCR cycle threshold (C_T) values. (2) This was a retrospective case-control study in a third-level health center in Mexico City with universal screening by RT-qPCR. The association of COVID-19 manifestations, preeclampsia, and preterm birth with maternal variables and C_T values were assessed by logistic regression models and decision trees. (3) Accordingly, 828 and 298 women had a negative and positive test, respectively. Of those positive, only 2.6% of them presented mild to moderate symptoms. Clinical characteristics between both groups of women were similar. No associations between C_T values were found for maternal features, such as pre-gestational BMI, age, and symptomatology. A significantly higher percentage of placental fibrinoid was seen with women with low C_Ts (<25; p < 0.01). Regarding perinatal outcomes, preeclampsia was found to be significantly associated with symptomatology but not with risk factors or C_T values (p < 0.01, aOR = 14.72). Moreover, 88.9% of women diagnosed with COVID-19 at <35 gestational weeks and symptomatic developed preeclampsia. (4) The data support strong guidance for pregnancies with SARS-CoV-2 infection, in particular preeclampsia and placental pathology, which need further investigation.

【 授权许可】

Unknown